問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

List

1457Cases

2017-05-01 - 2025-12-31

Others

AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    CVC /150mg tablet

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting1Sites

Terminated1Sites

彭成元
China Medical University Hospital-Taipei

未分科

2010-09-01 - 2013-10-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2008-04-01 - 2010-05-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-03-31 - 2021-12-31

Phase III

A randomized, double blind, placebo-controlled, multi-center, Phase III study investigating the efficacy and safety of ruxolitinib in Early Myelofibrosis patients with high molecular risk mutations

  • Condition/Disease

    Early Myelofibrosis

  • Test Drug

    JAKAVI

Participate Sites
3Sites

Terminated3Sites

2015-01-15 - 2023-06-06

Phase III

A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer.

  • Condition/Disease

    hormone receptor positive, HER2-negative, advanced breast cancer.

  • Test Drug

    LEE011

Participate Sites
8Sites

Terminated8Sites

2015-09-01 - 2021-02-19

Phase II

A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment.

  • Condition/Disease

    moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma

  • Test Drug

    PDR001

Participate Sites
4Sites

Not yet recruiting1Sites

Terminated3Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-03-31 - 2022-07-01

Phase II/III

Multicenter, open-label, study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril in pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction.

  • Condition/Disease

    pediatric patients with heart failure due to systemic left ventricle systolic dysfunction.

  • Test Drug

    LCZ696

Participate Sites
3Sites

Recruiting3Sites

2013-07-09 - 2024-01-07

Phase III

A phase III multicenter, randomized study of oral LDK378 versus standard chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-squamous non-small cell lung cancer

  • Condition/Disease

    Non small cell lung cancer

  • Test Drug

    LDK378

Participate Sites
7Sites

Terminated7Sites

2013-09-10 - 2015-10-31

Phase III

A 52-week treatment, multi-center, randomized, doubleblind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate / glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD

  • Condition/Disease

    moderate to very severe COPD

  • Test Drug

    QVA149

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

徐武輝
China Medical University Hospital

Division of Thoracic Medicine

2015-10-01 - 2020-04-30

Phase III

SOLAR-1: A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor (AI) treatment

  • Condition/Disease

    hormone receptor positive, HER2-negative advanced breast cancer

  • Test Drug

    BYL719/Faslodex

Participate Sites
3Sites

Terminated3Sites

曾令民
Taipei Veterans General Hospital

1 126 127 128 129 130 146
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB